Glass House Brands Inc. has announced its preliminary financial results for the third quarter of 2026, showcasing impressive growth in biomass production and revenue. The company reported a record biomass production of approximately 317,000 pounds, reflecting a significant increase from the previous quarter. This growth comes amid a challenging pricing environment in the California cannabis market, underscoring the company's resilience and operational improvements.
For the third quarter ending September 30, 2026, Glass House anticipates revenues of $56.8 million, a notable rise from $47 million in the second quarter and $26.2 million in the same quarter last year. The company also achieved a reduction in production costs, with the cost per pound dropping to approximately $110, down from $122 in the previous quarter.
In addition to the financial results, the company announced the resignation of John Nichols Jr. from its Board of Directors. Glass House expressed gratitude for his contributions and wished him well in future endeavors.
Background
Glass House Brands Inc. operates within the medicinal chemicals and botanical products sector, classified under SIC code 2833. The company, traded on the NYSE under the ticker GLAS, is based in Long Beach, California. It has been recognized as one of the fastest-growing cannabis companies in the U.S., focusing on the California market.
What the Filing Says
The SEC filing, dated October 19, 2026, details Glass House's preliminary unaudited financial results, highlighting record biomass production and a reaffirmation of its production guidance for the fiscal year. The report states, "Achieved Record Biomass Production of approximately 317,000 pounds and a further approximately 10% reduction in cost of production from the previous quarter." Additionally, the company noted that it expects to produce approximately 1 million pounds of biomass for the full year.
Impact
The financial results and operational updates from Glass House Brands may influence various stakeholders, including investors, competitors, and industry analysts. The company's ability to increase production while reducing costs could set a new standard in the medicinal chemicals and botanical products sector, prompting competitors to reassess their strategies.
What's Next
The filing does not specify what happens next regarding the resignation of John Nichols Jr. or any upcoming corporate actions. However, the company continues to focus on optimizing its operations and achieving its long-term production targets.
For more information, the full filing can be accessed under accession number 0001848731-26-000033.